Are you looking for some new additions to your investment portfolio that have the potential to supercharge your returns?
If you answered yes to that, then read on! That's because the ASX 200 shares listed below have been named as buys by analysts and tipped to race at least 20% higher from where they trade.
Here's what brokers are recommending and what they are saying about them right now:
The first ASX 200 share that is being tipped to rise strongly is regenerative medicine company Mesoblast.
Bell Potter sees huge potential in the company's stell cell therapies and believes its shares are being seriously undervalued at present. Though, it concedes that they are a higher risk option. Commenting on its assets, the broker said:
MSB has several late-stage clinical assets in multiple therapeutic indications. We expect progress of these towards commercial launch and monetisation to be its key value driver. MSB has organised non-dilutive financing through debt facility agreements and strategic licensing agreements with Tasly for China, Grunenthal for EU and LATAM. MSB's lead product is remestemcel-L for paediatric SR-aGvHD (steroid refractory acute graft versus host disease).
Bell Potter currently has a speculative buy rating and massive $3.40 price target on the company's shares. Based on its latest share price, this implies potential upside of approximately 100% for investors between now and this time next year.
Another ASX 200 share that could deliver a big return according to analysts is Worley.
It is a leading global provider of professional project and asset services in the energy, chemicals, and resources sectors.
Macquarie thinks that its shares are cheap at current levels. Particularly given its positive earnings growth outlook. It said:
Solid update re FY25 guidance affirmation, backlog up slightly & sales pipeline up ex VG CP2. Stock tracking oil price despite diversity in resources/chemicals & trades at >20% below EPS correlation and lagging global engg peers YTD. Stock now at 14.3x FY25E/13.4x FY26E P/E (vs 16.4x LTA).
Macquarie has an outperform rating and $15.85 price target on its shares. Based on its current share price of $12.90, this implies potential upside of 23% for investors over the next 12 months.
In addition, the broker is expecting an attractive fully franked dividend yield of approximately 4% over the period. This boosts the total potential return to approximately 27%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.